title: Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers.
abstract: Incretin effect enhancers are drugs used in the treatment of Type 2 diabetes and include GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors (gliptins). Variants in several genes were shown to be involved in the physiology of incretin secretion. Only two gene variants have evidence also from pharmacogenetic studies. TCF7L2 rs7903146 C>T and CTRB1/2 rs7202877 T>G minor allele carriers were both associated with a smaller reduction in HbA1c after gliptin treatment when compared with major allele carriers. After replication in further studies, these observations could be of clinical significance in helping to identify patients with potentially lower or higher response to gliptin treatment.
authors.affiliation: Department of Internal Medicine 4, Šafárik University, Faculty of Medicine, Rastislavova 43, 041 90 Košice, Slovakia.|Department of Internal Medicine 4, Pasteur University Hospital, Košice, Slovakia.
authors.forename: Ivan
authors.initials: I
authors.lastname: Tkáč
authors.affiliation: Department of Internal Medicine 4, Šafárik University, Faculty of Medicine, Rastislavova 43, 041 90 Košice, Slovakia.|Department of Internal Medicine 4, Pasteur University Hospital, Košice, Slovakia.
authors.forename: Ivana
authors.initials: I
authors.lastname: Gotthardová
mesh_terms: D002918:Chymotrypsin / Q000235:genetics / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D054795:Incretins / Q000819:agonists*; D051657:KCNQ1 Potassium Channel / Q000235:genetics / Q000378:metabolism; D000071185:Pharmacogenomic Testing; D000071184:Pharmacogenomic Variants; D020641:Polymorphism, Single Nucleotide; D058118:Transcription Factor 7-Like 2 Protein / Q000235:genetics / Q000378:metabolism; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D051657:KCNQ1 Potassium Channel; C496909:KCNQ1 protein, human; C544894:TCF7L2 protein, human; D058118:Transcription Factor 7-Like 2 Protein; D002918:Chymotrypsin; C117609:chymotrypsin B; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
keywords: CTRB1/2; GLP-1 receptor agonists; TCF7L2; Type 2 diabetes mellitus; gliptins; incretin effect